EBS — Emergent BioSolutions Inc.

—
NYSE · Health Care · Pharmaceuticals · CIK 1367644 ·
Last close
$5.61
Market Cap
$288.44M
52W High
$14.06
52W Low
$4.36
ADV30
1,049,610
Next earnings
2026-11-02

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 106,400,000 25,600,000 -37,300,000 -32,700,000 995,200,000 175,700,000 682,000,000
Jun 2026 226,800,000 129,700,000 66,200,000 -180,200,000 1,116,800,000 139,700,000 775,400,000
Mar 2026 149,700,000 77,700,000 10,500,000 6,800,000 1,320,400,000 160,300,000 797,300,000
Dec 2025 143,800,000 58,900,000 -15,700,000 -54,600,000 1,318,600,000 205,400,000 796,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$200,100,000
Investing CF
$-54,000,000
Financing CF
$-218,400,000
CapEx
$-11,700,000
Dividends Paid
—
Buybacks
$-27,200,000
EPS Diluted TTM
$-5.10
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-365,900,000
Inventory
$280,900,000
Receivables
$77,500,000
ST Investments
—
EBIT TTM
$-194,600,000
Pretax Income TTM
$-240,000,000
Interest Exp TTM
$45,400,000
Analysts
2

Yahoo Snapshot (yfinance, live)

Total Revenue
$649,100,032
EBITDA
$125,700,000
Free Cash Flow
$196,687,504
Enterprise Value
$649,576,000
Total Cash
$175,700,000
Total Debt
$513,700,000
Shares Out
51,415,182
Trailing EPS
$-5.00
Book Value
$6.11
ROE
-58.2%
ROA
1.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 705,200,000 112,300,000 52,600,000 1,318,600,000 796,000,000 522,600,000 170,600,000
Dec 2024 1,013,600,000 -81,500,000 -190,600,000 1,389,700,000 906,900,000 482,800,000 58,700,000
Dec 2023 1,023,000,000 -201,500,000 -760,500,000 1,823,200,000 1,173,900,000 649,300,000 -206,300,000
Dec 2022 1,076,100,000 -163,300,000 -211,600,000 3,166,300,000 1,778,600,000 1,387,700,000 -34,100,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
$1,116,800,000
Forward EPS
$1.05

Max Pain — expiry 2027-01-15

max pain strike: $6.00 · spot: $5.50 · call oi: 5,091 · put oi: 567
Expected Move to 2027-01-15: ±$1.28 (23.18%) — implied range $4.22 – $6.78 · ATM straddle on $5.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MPLT MapLight Therapeutics, Inc. $286.78M $6.57 —
EVMN Evommune, Inc. $290.28M $7.02 —
FULC Fulcrum Therapeutics, Inc. $286.43M $3.75 —
VCRE Vicore Pharma Holding AB $285.02M $10.12 —
BNTC Benitec Biopharma Inc. $284.35M $8.15 —

News headlines (Yahoo Finance, 1h cache)

Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola
2026-11-16 21:01 · Yahoo
Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference
2026-11-10 13:00 · Yahoo
Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs on ...
2026-11-05 07:01 · Yahoo
Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War
2026-11-04 21:05 · Yahoo
Emergent BioSolutions Inc. Q3 2026 Earnings Call Summary
2026-11-03 13:30 · Yahoo
Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors
2026-11-03 12:02 · Yahoo
Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript
2026-11-03 05:28 · Yahoo
Emergent Biosolutions: Q3 Earnings Snapshot
2026-11-03 04:25 · Yahoo
Emergent Biosolutions Q3 Earnings Call Highlights
2026-11-02 23:13 · Yahoo
Emergent Biosolutions Reports Third Quarter 2026 Financial Results
2026-11-02 21:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.